A Phase 2 interventional study of Cemiplimab and Carboplatin in Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Swiss Cancer Institute. Recruiting at 18 sites in Switzerland. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Swiss Cancer Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 40 under way, 12 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.
Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 54th largest by planned enrollment of the 251 interventional ones that give a count, is one of 6 that started in 2026, is one of 149 in phase 2, reaches primary completion later than 30 of the 39 other live ones, and was the 264th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
People's Hospital of Quzhou · Sites in China
Ages 18–75
Latin American Cooperative Oncology Group · Sites in Brazil
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Nir Peled · Sites in Israel
Ages 18–99
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
272 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 177 · Phase 3 50 · Phase 4 3
First in 1996; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 55 across the 251 interventional studies. Of the 188 that completed or were terminated, 78 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 272 have an industry lead sponsor. The 10 most frequent:
Swiss Cancer Institute is the lead sponsor of 27 studies on the registry; 12 are open to participants now.
Swiss Cancer Institute has 8 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
9 of the studies testing carboplatin in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT05654454Phase 3Mabscale, LLCA Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metastatic non-small cell lung cancer is often treated with a combination of chemotherapy and immunotherapy. In patients over the age of 70, some are already in poor health and frail, requiring assistance with daily activities, for example. Older and/or frail individuals often do not tolerate standard-dose chemotherapy well, and their risk of side effects is higher than that of younger patients.
For this reason, the SAKK 18/24 study is investigating how effective and safe chemotherapy is in patients over 70 years of age when the chemotherapy drugs are administered at lower doses than usual. The aim of the study is to find a potentially effective and well-tolerated treatment for older people with metastatic non-small cell lung cancer.
This randomized, open-label, phase II clinical trial evaluates the efficacy, safety, and overall treatment utility of reduced-dose platinum-doublet chemotherapy (rdCT) in combination with cemiplimab (cemi) versus cemiplimab monotherapy in older and/or frail patients with stage III/IV non-small cell lung cancer (NSCLC) and PD-L1 expression \<50%. The study specifically addresses a major evidence gap for a vulnerable patient population often underrepresented in registrational trials.
Cemiplimab in combination with full-dose carboplatin-based doublet chemotherapy is a Swissmedic-approved first-line treatment for advanced NSCLC, based on data from EMPOWER-Lung 03. However, full-dose chemotherapy regimens (e.g., carboplatin AUC 5 + pemetrexed, paclitaxel, or gemcitabine) are frequently associated with prohibitive toxicity in elderly and/or frail patients. Over half of all newly diagnosed mNSCLC cases occur in individuals aged 70 or older, many of whom present with frailty or multimorbidity. While atezolizumab monotherapy has shown a survival benefit over single-agent chemotherapy in older, treatment-ineligible patients (IPSOS trial), overall outcomes remain suboptimal.
In clinical practice, rdCT regimens are commonly used in this patient population, despite limited prospective evidence. The present study uses the G8 screening tool-a validated geriatric assessment instrument-to identify patients at risk for increased treatment toxicity and to support treatment adaptation.
Objectives The primary objective is to compare overall survival (OS) between rdCT + cemiplimab and cemiplimab monotherapy. Secondary objectives include comparison of progression-free survival (PFS), objective response rate (ORR), adverse events (AE), health-related quality of life (HRQoL), and overall treatment utility (OTU).
Design and Interventions This is a multicenter, randomized, open-label, parallel-group study enrolling approximately 156 patients (78 per arm) across \~17 sites in Switzerland. Eligible patients are ≥70 years old, have a G8 score ≤14 or are deemed unsuitable for full-dose chemotherapy, and have advanced or metastatic NSCLC without actionable genomic alterations and PD-L1 \<50%.
Patients are randomized to one of two arms:
Cemiplimab maintenance continues until disease progression, unacceptable toxicity, or a maximum of 2 years. Treatment beyond progression is permitted in cases of oligoprogression amenable to local therapy.
Assessments Radiologic response assessments (CT ± CNS imaging) are performed every 6 weeks until week 12, then every 9 weeks until week 30, and every 12 weeks thereafter. HRQoL is assessed using NFLSI-17 and QLQ-ELD14 at baseline, every 6 weeks to week 12, every 9 weeks to week 30, and every 24 weeks thereafter.
Overall Treatment Utility (OTU) is assessed at the same intervals and incorporates:
Statistical Considerations With 128 OS events, the study is powered (80%) to detect an increase in median OS from 10.3 months (based on IPSOS trial) to 16 months in the experimental arm (one-sided alpha = 0.05). Sample size: 156 patients (allowing 5% attrition).
Time-to-event outcomes will be analyzed using Kaplan-Meier methods with log-rank tests and Cox proportional hazards models. Response rates and adverse events will be compared using Fisher's exact or chi-square tests. Continuous variables (e.g., HRQoL scores) will be analyzed using Wilcoxon rank-sum or linear regression (mixed models as appropriate).
Quality Assurance and Data Integrity
Although not formally a registry, the trial employs registry-like quality control elements:
Conclusion This trial responds to the pressing need for evidence-based, tolerable, and effective treatment strategies for older and/or frail patients with advanced NSCLC. By leveraging geriatric screening tools and integrating real-world adaptations such as reduced-dose chemotherapy, this study aims to optimize oncologic outcomes while preserving quality of life and functional status. Findings will inform clinical decision-making for a frequently excluded patient group in oncology research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must be suitable to receive reduced-dose carboplatin-doublet chemotherapy in combination with immunotherapy including adequate bone marrow, renal and hepatic function as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-squamous histology: * carboplatin IV AUC 3 day 1 * pemetrexed IV 300 mg/m2 day 1 * cemiplimab IV 350 mg, day 1 Every 3 weeks, for 4 cycles, followed by maintenance treatment with cemiplimab with or without pemetrexed (at same dose and interval as above). Squamous histology: * carboplatin IV AUC 1.5 day 1, d8 * gemcitabine IV 600 mg/m2 day 1, d8 * cemiplimab IV 350 mg, day 1 Every 3 weeks, for 4 cycles, followed by maintenance treatment with cemiplimab (350 mg q3w) Any histology: * carboplatin IV AUC 1.5 day 1, d8 * paclitaxel IV 50 mg/m2 day 1, d8 * cemiplimab IV 350 mg, day 1 Every 3 weeks, for 4 cycles, followed by maintenance treatment with cemiplimab (350 mg q3w)
Drug: Cemiplimab · Drug: Carboplatin · Drug: Pemetrexed & Gemcitabine · Drug: Paclitaxel
cemiplimab IV 350 mg, day 1 Every 3 weeks (max. 2 years)
Drug: Cemiplimab
cemiplimab IV 350 mg, day 1
carboplatin IV AUC 3 day 1
Drug pages: PemetrexedStudies of PemetrexedPemetrexed pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
pemetrexed IV 300 mg/m2 day 1 gemcitabine IV 600 mg/m2 day 1, d8
paclitaxel IV 50 mg/m2 day 1, d8
Progression-free survival (PFS)
PFS is defined as time from randomization to confirmed tumor progression according to RECIST 1.1 or death due to any cause. Patients not experiencing an event will be censored at their last tumor assessment before starting a new anti-cancer treatment line (if any).
Time frame: From the date of randomization until the date of confirmed tumor progression according to RECIST 1.1 or death from any cause, assessed up to 1 year after end of treatment.
Overall survival (OS)
OS is defined as time from randomization to death due to any cause. Patients not experiencing an event will be censored at their last date known alive.
Time frame: From the date of randomization until the date of death from any cause, assessed up to 1 year after end of treatment.
Objective response rate (ORR)
Objective response is defined as any complete response (CR) or partial response (PR) according to RECIST 1.1 criteria achieved during treatment. Patients without any tumor assessment or with non-evaluable response during treatment will be considered as failures for this endpoint
Time frame: From the date of randomization until the end of treatment, estimated up to 1 year after randomization.
Started Apr 2026 (actual). Primary completion is estimated for Sep 2028, 29 months after the start.
Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 29 months is below that.
Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carboplatin
Carcinoma, Non-Small-Cell Lung →
Swiss Cancer Institute